2025 UK Veterinary Guide: Top 7 Prescription Adrenal Replacement & Corticosteroid Treatments for Dogs (Florinef, Percorten-V, Prednisolone, Dexamethasone, Cortrosyn) — Clinical Dosing, Monitoring & Selection Criteria

Florinef’s low-dose oral fludrocortisone remains a cornerstone for chronic mineralocorticoid replacement in canine hypoadrenocorticism because it combines predictable daily dosing with easy at-home administration and lower upfront cost than depot injectables. In this 2025 British guide it stands out for owners prioritising tight day-to-day control and affordability compared with injectable options like Percorten‑V or Zycortal, though it requires more frequent clinical monitoring of electrolytes and blood pressure. Compared with systemic glucocorticoids (prednisolone, dexamethasone), Florinef’s targeted mineralocorticoid action reduces unnecessary glucocorticoid exposure and related side effects.

Percorten‑V is a long-established DOCP injectable that delivers dependable monthly mineralocorticoid replacement with a long clinical track record, making it a market leader for dogs where owner-administered oral therapy is impractical. In the 2025 British context its technical advantage is the extended-duration injectable format providing consistent electrolytic control versus daily Florinef tablets, although it can be more expensive per dose and typically requires clinic visits or trained administration. Compared with Zycortal, Percorten‑V’s legacy status means broad clinician familiarity, but Zycortal may offer newer licensure and flexible dosing advantages in some practices.

Veterinary prednisolone tablets remain the most versatile and cost‑effective systemic glucocorticoid for anti‑inflammatory and immunosuppressive therapy in dogs, prized for flexible oral dosing and widespread availability across strengths. In this guide prednisolone is highlighted for day‑to‑day therapeutic management where long-term control is needed at lower cost than higher‑potency injectables like dexamethasone, though it has a higher risk of systemic side effects than locally active steroids such as budesonide. When paired with mineralocorticoid agents (Florinef or DOCP products) it allows tailored glucocorticoid replacement while keeping monitoring requirements and expenses manageable for most owners.

Dexamethasone injection is a potent, fast‑acting corticosteroid essential for emergency care, IV dosing and diagnostic protocols where immediate glucocorticoid effect is required; its high potency and predictable parenteral absorption make it indispensable in acute presentations. In the 2025 British guide it is positioned as the preferred injectable for rapid suppression or replacement testing compared with oral prednisolone, although its strength and longer biologic effect demand careful dose calculation and monitoring to avoid overtreatment. Financially it is typically inexpensive per vial, but clinical use often requires staff‑led administration and observation, raising procedural costs relative to oral options.

Cortrosyn (tetracosactide) occupies a unique role as the diagnostic standard for ACTH stimulation testing — essential for confirming adrenal insufficiency or monitoring replacement therapy adjustments in dogs. In this 2025 British guide it is emphasised not as a therapy but as a monitoring tool that complements therapeutic agents on the list (Florinef, DOCP products) by enabling objective assessment of adrenal response; its technical advantage is validated, reproducible stimulation over empirical clinical assessment. While more costly per test than routine blood checks, Cortrosyn’s diagnostic clarity often reduces longer‑term treatment uncertainty and inappropriate medication changes.

Zycortal is a modern DOCP formulation licensed specifically for canine hypoadrenocorticism and designed for owner‑friendly administration with dosing schedules that can reduce clinic visits, offering a compelling balance of efficacy and convenience in the UK market. In this guide Zycortal is highlighted as a contemporary alternative to Percorten‑V, often providing more flexible administration options and competitive total cost of care thanks to reduced monitoring burden and subcutaneous dosing that some owners can perform at home. Technically it matches other DOCPs for mineralocorticoid effect but often scores higher on usability and adherence, which can improve long‑term outcomes.

Budesonide capsules are recommended in cases where potent glucocorticoid effect is needed with reduced systemic exposure because of high first‑pass hepatic metabolism, making them especially useful for steroid‑responsive enteropathies and chronic GI disease in dogs. In the 2025 British context budesonide is presented as a technical and financial middle ground: typically more costly per dose than prednisolone but with a lower incidence of systemic side effects, potentially reducing downstream monitoring and comorbidity costs. Compared with inhaled or high‑potency injectables (dexamethasone), budesonide offers targeted systemic control with improved safety for long‑term use when clinical response permits.